ProFactor Pharma LTD | Transforming treatment of haemophilia

ProFactor Pharma

Transforming treatment of haemophilia

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia. Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

More About Us

According to the World Health Organisation (WHO) almost three quarters of the haemophilia patient population receive inadequate or no treatment at all.

Learn About Haemophilia

Recent News

PFP secures new investment of £2m to achieve pre-clinical trials

Oct 30, 2019 | News

ProFactor Pharma Ltd (PFP) is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd...

Press Release March 2015 – Penrose enquiry

Dec 16, 2015 | News

Hope for Haemophiliacs Despite the controversy and disappointment emerging from the final report of the Penrose Inquiry into contaminated blood, which led to infection and death of hundreds of Scots, including haemophiliacs, new hope is emerging in a small laboratory...